LLPC geassocieerde studies

Open studies

Naam GCT3013-02

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; 
DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma 

Status Open

The study is open at Erasmus MC (;;; and UMCU (; The study will also open at: MUMC (; VUMC (, and LUMC (

Studie info

De study is in the escalation phase for (ask for a slot!):
Arm 1 = 1st line DLBCL epcoritamab plus R-CHOP
Arm 2 = rr FL epcoritamab plus lenalidomide-rituximab
Arm 3 = 1st line FL epcoritamab plus R-Bendamustine
Arm 4 = rr DLBCL ASCT eligible : epcoritamab plus R-DHAC
De study is in the expansion phase for (does not work with slots):
Arm 5 = rr DLBCL not eligible for ASCT: epcoritamab plus gemcitabine-oxaliplatin

Documenten In en exclusiecriteria
Naam GEN3009

Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A
First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts

Status Open
Deelnemers Open in VUMC (
Gaat ook open in Utrecht, Rotterdam  en Maastricht
Documenten In en exclusiecriteria


Short name TRANSCEND WORLD (Celgene JCAR017-BCM-001)
Studie title A phase 2, single-arm, multi-cohort, multicenter trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-Cell non-Hodgkin lymphoma.
Status Open
Deelnemers De studie is open in het Erasmus MC (;;
Studie info Open zijn nu cohort 4 (firstline therapy high grade B-cell lymphoma with MYC and BCL2 and / or BCL6 translocations) en cohort 5 (PCNSL who failed therapy with high dose chemotherapy and ASCT; no prior WBRT)

Aanvullende in- en exclusie criteria
Informeer eerst of er een slot beschikbaar is voor de verschillende cohorten!


Naam GCT3013-01
Titel A phase 1-2, open-label, dose-escalation and expansion trial of GEN3013 (bispecific antibody CD20xCD3, epcoritamab) in patients with relapsed, progressive or refractory B-Cell lymphoma.
Status Open
Deelnemers The study is open at Erasmus MC (;;; VUMC (;, UMCU (; and MUMC (
Studie info The study is in the expansion phase. Patients with relapse or refractory aggressive B-NHL (DLBCL, HGBCL (DH/TH), PMBCL, Follicular lymphoma grade 3B) or Follicular lymphoma (grade 1-3A) or mantle cell lymphoma may be included, after at least 2 prior lines of therapy. For aggressive B-NHL ask for a slot reservation! For FL and MCL this is not necessary.
Documenten In- en exclusie criteria
Naam CDK9
Titel A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects with Relapsed or Refractory Haematological Malignancies.
Status Open
Deelnemers De studie is open in het AMC en het Antonius Ziekenhuis Nieuwegein
Documenten Eligibility criteria


Naam EDO-S101-1001
Titel Phase 1 study to investigate the safety, pharmacokinetic profiles and efficacy of EDO-S101 (tinostamustine), a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule in relapsed/refractory hematological malignancies.
Status Open

The study is open at Erasmus MC (;; and VUMC (;
The study will also open at LUMC

Studie info

The study is in stage 2 = expansion phase and is open for:
Cohort 2: rr Hodgkin lymphoma after ≥ 3 prior lines therapy
Cohort 4: rr CTCL (MF; SS), ≥ 1 and ≤ 4 prior lines of systemic therapy

Documenten In- and exclusion criteria
Naam R/R CLL
Studie title Phase 1b/2 GEN3013 Monotherapy Study De
Studie drug Epcoritamab (subcutaneous CD3xCD20

Currently open in: Amsterdam UMC, AMC
Will be opened at: Universitair Medisch Centrum Groningen & Maastricht University Medical Center

Studie info R/R CLL after receiving at least 2 prior lines of systemic antineoplastic therapy, including treatment with (or intolerance of) a BTK inhibitor and with active CLL disease that needs treatment per iwCLL2018
Studie docs In- and exclusion criteria

Planned trials


Naam CMAK638X2101
Titel A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies, hematological malignancies include relapsed or refractory DLBCL or FL with or without EZH2 mutation and relapsed or refractory T-cell lymphoma
Status Gepland


Naam NP39461
Titel Open-label, dose escalation/expansion phase IB study to evaluate the safety, pharmacokinetics, and clinical activity of the combination of RO6870810 and venetoclax, with or without rituximab, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Status Gepland
Documenten Protocol synopsis
In- en exclusiecriteria


Gesloten Studies

Naam ACT15320
Titel A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma.
Status Closed
Deelnemers MUMC
Naam BELINDA (CCTL019H2301)
Titel Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial
Status Closed
Deelnemers AMC en UMCUtrecht
Documenten Flow en inclusie criteria
Naam TRANSFORM (Celgene JCAR017-BCM-003)
Titel A global randomized multicenter phase 3 trial to compare the efficacy and safety of JCAR017 (Car-T-cell) to standard of care (autologous SCT) in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas
Status Closed
Deelnemers Erasmus MC (;;
Documenten In- en exclusie criteria


Naam Harbour
Studie title Phase 1b study with blinatumumab in combination with pembrolizumab treatment in 3th line DLBCL
Status Closed
Deelnemers The study is open at Erasmus MC (;;; MUMC ( and Radboudumc (
Studie info The study is on hold in the dose escalation phase. The dose expansion phase will probably start 01-01-2021
Studie docs In- and exclusion criteria